861880-99-1

Upstream product

• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 1149370-96-6 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol hydrochloride 

Downstream Products

• 861879-29-0 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-((1R)-1-phenylethyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide 
• 861879-21-2 C₂₇H₂₅N₃O₅ 
• 861879-15-4 C₂₆H₂₂ClN₃O₅ 
• 861879-22-3 C₂₆H₂₂ClN₃O₅ 
• 861879-28-9 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-((1S)-1-phenylethyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide 
• 861879-16-5 C₂₆H₂₃N₃O₅ 
• 861879-20-1 C₂₇H₂₅N₃O₅ 
• 1016989-26-6 C₂₆H₂₂FN₃O₅ 
• 861879-19-8 C₂₇H₂₅N₃O₅ 
• 861879-25-6 C₂₇H₂₅N₃O₅ 
• 861879-14-3 C₂₆H₂₂ClN₃O₅ 
• 861879-26-7 C₂₈H₂₇N₃O₅ 

Relevant academic research and scientific papers

BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE

Selected benzomorpholine compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical composit

Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis

Angiogenesis is vital for solid tumor growth, and its prevention is a proven strategy for the treatment of disease states such as cancer. The vascular endothelial growth factor (VEGF) pathway provides several opportunities by which small molecules can act as inhibitors of endothelial proliferation and migration. Critical to these processes is signaling through VEGFR-2 or the kinase insert domain receptor (KDR) upon stimulation by its ligand VEGF. Herein, we report the discovery of 2,3-dihydro-1,4-benzoxazines as inhibitors of intrinsic KDR activity (IC50 50 a potent (KDR: a promising platform for generating kinase-based antiangiogenic therapeutic agents.